Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Burkitt Lymphoma 7Lymphoma, Mantle-Cell 3Leukemia, Biphenotypic, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmacytoma 2Hodgkin Disease 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1POEMS Syndrome 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Vincristine 2Inotuzumab Ozogamicin 2Doxorubicin 2Dexamethasone 2Cyclophosphamide 2pegaspargase 1merphos 1dexamethasone acetate 1dexamethasone 21-phosphate 1azathiopurine 1auricularum 1Thioguanine 1Prednisone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Lenalidomide 1Etoposide 1Cytarabine 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × auricularum × Clear all
NCT01190930 2026-05-22

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡